Senate Resolution 1302 recognizes the week of May 4, 2025, as Tardive Dyskinesia Awareness Week in Florida. The resolution explains that tardive dyskinesia (TD) is a movement disorder associated with prolonged use of antipsychotic medications, and it highlights the condition’s symptoms, prevalence, and the importance of early screening and diagnosis. It also notes that TD can affect people being treated for serious mental illnesses such as bipolar disorder, major depressive disorder, schizophrenia, and schizoaffective disorder.
The resolution encourages individuals who experience uncontrollable, abnormal, repetitive movements to consult a health care provider. It references clinical guidance from the American Psychiatric Association recommending routine TD screening for patients taking antipsychotics or showing abnormal movements, and it points to FDA-approved treatments that may help manage symptoms and improve quality of life. The measure is primarily commemorative and educational rather than regulatory, aiming to increase public and medical awareness of TD and promote best-practice care.
Impact
This resolution does not amend Florida statutes, create a new regulatory program, or impose legal duties on health care providers or patients. Its practical effect is to designate an awareness week and use the Senate’s platform to encourage screening, diagnosis, and treatment of tardive dyskinesia among people taking antipsychotic medications. The affected parties are patients with serious mental illness, prescribers, psychiatrists, and other health care professionals who may encounter TD symptoms.
Sentiment
The available text suggests a strongly supportive and public-health-oriented sentiment. The resolution is framed around awareness, early detection, and improved care, and it cites medical guidance and FDA-approved treatments to underscore the importance of recognizing TD. There is no recorded committee debate or vote history in the provided materials, so no opposing sentiment is documented.
Contention
No specific contention is shown in the provided record, and there are no committee transcripts or votes indicating disagreement. If any concerns were to arise, they would likely center on whether a commemorative resolution is the appropriate vehicle for a health-awareness message, but the bill text itself presents the measure as noncontroversial and informational. The resolution’s focus on mental health treatment and antipsychotic use may be sensitive in general, but no opposition is documented here.